Hi Suziki
I have no idea which patients have been resected. I think the overall median survival data is 16 months which is greater than current best practice of 9-11 months. And as some of the patients continue to live the median survival rate will continue to increase as well. So, in effect the OS data can show close to double the same average for current best practice with chemo only. In other words it wouldn’t surprise me that OS data will now show closer to 18 months, closer to double the average OS data for chemo only. IMO this is important data as it demonstrates significant clinical benefit of the Oncosil device.
CE Mark Odds, page-134
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.002(25.0%) |
Mkt cap ! $20.38M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.6¢ | $92.85K | 14.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 10095667 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2789969 | 4 |
View Market Depth
| Last trade - 10.48am 16/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |